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Abstract
Adequate differentiation or decidualization of endometrial stromal cells (ESC) is critical for successful pregnancy in humans
and rodents. Here, we investigated the role of leukemia inhibitory factor (LIF) in human and murine decidualization. Ex vivo
human (H) ESC decidualization was induced by estrogen (E, 10
28 M) plus medroxyprogesterone acetate (MPA, 10
27 M).
Exogenous LIF ($50 ng/ml) induced STAT3 phosphorylation in non-decidualized and decidualized HESC and enhanced
E+MPA-induced decidualization (measured by PRL secretion, P,0.05). LIF mRNA in HESC was down-regulated by
decidualization treatment (E+MPA) whereas LIF receptor (R) mRNA was up-regulated, suggesting that the decidualization
stimulus ‘primed’ HESC for LIF action, but that factors not present in our in vitro model were required to induce LIF
expression. Ex vivo first trimester decidual biopsies secreted .100 pg/mg G-CSF, IL6, IL8, and MCP1. Decidualized HESC
secreted IL6, IL8, IL15 and MCP1. LIF (50 ng/ml) up-regulated IL6 and IL15 (P,0.05) secretion in decidualized HESC
compared to 0.5 ng/ml LIF. In murine endometrium, LIF and LIFR immunolocalized to decidualized stromal cells on day 5 of
gestation (day 0=day of plug detection). Western blotting confirmed that LIF and the LIFR were up-regulated in intra-
implantation sites compared to inter-implantation sites on Day 5 of gestation. To determine the role of LIF during in vivo
murine decidualization, intra-peritoneal injections of a long-acting LIF antagonist (PEGLA; 900 or 1200 mg) were given just
post-attachment, during the initiation of decidualization on day 4. PEGLA treatment reduced implantation site decidual area
(P,0.05) and desmin staining immuno-intensity (P,0.05) compared to control on day 6 of gestation. This study
demonstrated that LIF was an important regulator of decidualization in humans and mice and data provides insight into the
processes underlying decidualization, which are important for understanding implantation and placentation.
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Introduction
Successful implantation of a blastocyst and subsequent formation of
a functional placenta leading to the establishment of pregnancy in
women, is dependent on the adequate decidualization of endometrial
stromal cells (ESC) [1]. Decidualization describes the differentiation
and proliferation of ESC into morphologically and functionally
distinct decidual cells [1]. In women, decidualization is initiated
during the mid-late secretory phase by progesterone, independent of
the presence of an implanting blastocyst, however the decidua of
pregnancy is only formed following blastocyst implantation. In
contrast,inrodents decidualization beginsonlyfollowing implantation
of a blastocyst into the endometrium of a hormonally primed uterus.
The critical molecular interactions that regulate decidualization
are largely unknown, although it has been shown that, in addition
to ovarian hormones, locally and temporally produced products
such as cytokines and growth factors (eg. interleukin [IL] 11,
relaxin, prostaglandin E2, activin A, and corticotrophin-releasing
hormone) progress decidualization [2].
Leukemia inhibitory factor (LIF), an IL6-type cytokine, is one of
a very few cytokines shown to be critical for implantation in mice
[3]. LIF mRNA and protein is maximally expressed in the murine
endometrial glandular epithelium just prior to blastocyst implan-
tation [4,5]: LIF
2/2 female mice are infertile due to implantation
failure: blastocysts cannot adhere to the endometrial luminal
epithelium [6].
Likewise in women, LIF is maximally expressed by the luminal
and glandular epithelium during the mid-secretory phase of the
menstrual cycle, the period during which the uterus is receptive to
an implanting blastocyst [3]. Lower levels of LIF are found in
uterine flushings from some infertile women compared to fertile
women [3] and we have demonstrated that LIF regulates the
adhesive properties of human endometrial epithelial cells [7]
supporting a role for LIF in human blastocyst attachment to the
endometrium, similar to mice.
Whether LIF has a role in decidualization is not clear. In women,
LIF protein is presentin the endometrial stroma during the mid-late
secretory phase of the menstrual cycle, but at considerably lower
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protein are expressed in the first trimester decidua [3]. In the only in
vitro study using human (H) ESC, exogenous LIF had no effect on 8-
bromo cyclic adenosine monophosphate (cAMP) analog induced
decidualization [8], however it is not known whether LIF has a role
in progesterone induced decidualization. Certainly, both the
progesterone and cAMP pathways are required for decidualization
[9], however progesterone rather than cAMP is the main
physiological inducer of decidualization in vivo; although cAMP
may ‘prime’ HESCs to the action of progesterone [10]. Further,
cAMP and progesterone may use different pathways during
decidualization [10,11]. Additionally, other cytokines have been
shown to progress progesterone induced decidualization whilst
having no effect on cAMP induced decidualization [12,13].
The role of LIF in murine decidualization is also unclear.
Unlike in women, in mice decidualization of ESC occurs post-
implantation. LIF
2/2 female mice do not undergo artificial
decidualization [14] and intraluminal administration of a short-
acting LIF inhibitor during the peri-implantation period results
in less extensive desmin filaments (decidual marker) than in the
control mice [15]. Further, intraluminal injections of LIF into
Fox2a null females partially rescues the formation of a
deciduoma during artificial decidualization [16]. Conversely
however, LIF inhibits decidualization of murine stromal cells in
vitro [17]. We have previously used a long-acting, polyethylene
glycol (PEG) conjugated LIF antagonist (PEGLA) to block LIF
action in the endometrial luminal epithelium during the peri-
implantation period in mice. This resulted in implantation failure
[18,19] replicating the LIF
2/2 phenotype [6], however the effect
of LIF inhibition during the initiation of decidualization is
unknown.
Here we aimed to investigate whether LIF has a role in
decidualization in humans and in mice and to define the
mechanism by which this may occur. Specifically, we aimed to
determine whether LIF could alter progesterone induced decid-
ualization of HESC ex vivo, and to determine the effect of LIF
inhibition on in vivo decidualization in mice using a long-acting LIF
antagonist (PEGLA).
Materials and Methods
Ethics Statement
Human ethics. Written informed consent was obtained from
each patient and the study was approved by the Southern Health
Research and Ethics Committee (#09317B; #06014C) at Monash
Medical Centre Melbourne, Australia.
Animal ethics. All procedures were approved by the Monash
Medical Centre Animal Ethics Committee (#MMCB2007/21)
and followed the NHMRC Australian Code of Practice for the
Care and Use of Animals for Scientific Purposes.
Human tissue collection
Endometrial biopsies were collected from women with regular
menstrual cycles between days 8–24. The women had no steroid
treatment for at least 2 months prior to tissue collection. The
biopsies were examined by an experienced gynaecological
pathologist to confirm that they had no apparent endometrial
dysfunction. Normal 1
st trimester decidual tissue was collected
from healthy women undergoing elective termination of pregnan-
cy (amenorrhea: 7–11 weeks). Endometrial and decidual biopsies
were either fixed in 10% neutral buffered formalin for 18 h and
processed to wax or placed in Dulbecco’s Modified Eagle’s
Medium/F12 (DMEM/F12 GIBCOH Invitrogen, Mt Waverly,
Vic, Australia).
LIF and LIFRa immunohistochemistry in human
endometrium
Paraffin-embedded, formalin-fixed endometrial tissue from the
mid-late secretory phase of the menstrual cycle and 1
st trimester
decidua (n=4–6 per group) were dewaxed in histosol and
rehydrated in ethanol. LIF was immunolocalized as previously
described [20] except that the primary antibody was incubated
overnight at 4uC and a goat anti-rabbit secondary (Vector, Vector
Laboratories Inc, Burlingham, California, USA) was used. LIF
receptor aLIFR) was immunolocalized as follows: endogenous
hydrogen peroxidase activity was quenched using 3% H2O2 in
methanol for 10 mins at room temperature. Sections were blocked
in non-immune serum (10% horse, 6% fetal calf and 2% human
serum in 0.1%Tween-20 Tris-buffered saline [TBS]) for 1 hr at
room temperature (RT) before the primary antibody (LIFRa,
2.5 mg/ml, #AF-249-NA R&D Systems) was applied for 1 h and
incubated at RT. A non-immune goat IgG isotype control diluted
to a matching concentration as the primary antibody was
included. After stringent washing with 0.6% Tween 20 in TBS,
biotinylated horse anti-goat secondary antibody (1:200, Vector)
was applied for 30 min at RT followed by a 30 min incubation
with streptavidin-biotin complex/HRP (Vector) before sections
were stained with the substrate 393-diaminobenzidine (K3466,
DAKO). Quality controls were included in each run.
HESC in vitro decidualization
HESC were isolated from tissue by enzymatic digestion and
filtration as previously described [13,21,22]. HESC isolated by
this method are 97% pure as assessed by immunostaining for
cytokeratin and vimentin [13]. Cells were plated in 25 cm
2 flasks
or 12 well plates (NUNC, In Vitro technologies, Noble Park
North, VIC, Australia) and grown to confluence. Once confluent,
HESC were cultured overnight in low serum media (DMEM/
F12+2% charcoal stripped fetal calf serum [FCS], 1% antibiotics
and antimycotic) to suppress the production of any endogenous
factors. Decidualization was conducted in low serum media to
minimize cell proliferation. Cells were treated with 10
28 M
estradiol 17b (E; Sigma Chemical Co., St Louis, MO, USA) plus
10
27 M medroxy-progesterone acetate (MPA; Sigma) for 14
days. The media containing treatments was replenished every
48 h and supernatant was collected, centrifuged at 1606g to
pellet any non-adherent cells and stored at 220uC. On Day (D)
14, cells were washed twice with ice-cold sterile Phosphate
Buffered Saline (PBS, calcium and magnesium free) before being
lysed in 200 ml ice-cold Universal immunoprecipitation (UIP) lysis
buffer (50 mM Tris base, 150 mM NaCl, 2 mM EDTA, 2 mM
EGTA, 25 mM NaF, 0.2% TritionX-100, 0.3% Nonidet P-40,
25 mM ß-glycerolphosphate [pH 7.5]) containing Protease In-
hibitor Mixture Set III (1:500; Calbiochem, San Diego, CA),
centrifuged at 96606g to pellet cell membrane and cell debris.
Supernatants containing the protein lysate were assayed for total
protein using the BCA Protein Assay Kit (Pierce, Quantum
Scientific, Rockford, IL).
Prolactin (PRL) secretion is used to measure the degree of in vitro
HESC decidualization [23]. Supernatant from decidualizing
HESC was concentrated 10-fold overnight (SpeediVac SC100,
Savant, GMI Inc., Minneapolis, USA) and PRL secretion
measured quantitatively by ELISA (Bioclone Australia Pty Ltd.,
Marrickville, NSW, Australia) according to the manufacturer’s
instructions. The lower detection limit of this assay is 50 mIU/L
and the inter- and intra-assay variabilities were 5.3 and 3.0%,
respectively. PRL secretion was normalized to total cellular
protein.
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decidualized HESC
Total RNA was isolated from cultured HESC (media alone, E,
E+MPA-treated; n=4/group) using the RNeasy Minikit (QIA-
GEN Sciences, Germantown, Maryland, USA) according to the
manufacturer’s instructions. Genomic DNA was digested using the
DNAfree kit (Ambion) according to the manufacturer’s instruc-
tions. RNA samples were analysed by spectrophotometry
(Nanodrop, Perkin Elmer, Waltham, Massachusetts, USA) at an
absorbance ratio of A260/280 nm to determine RNA concentra-
tion, yield and purity. cDNA was synthesized from total RNA
(500 ng) using Superscript III reverse transcriptase (Invitrogen)
and analyzed by spectrophotometry at an absorbance ratio of
A260/280 nm to determine concentration and purity.
Polymerase chain reaction. PCR reactions were performed
using PCR express machine (Thermo Fisher Scientific Inc., Milfred,
MA, USA) and GoTaq master mix (Promega) according to the
manufacturer’s instructions. HESC cDNA was analysed for LIF,
LIFR and 18 s using reaction conditions of an initial denaturation at
95uC for 5 mins, followed by 30 (LIF, LIFR) or 22 (18 s) cycles of:
denaturation, 94uC for 1 min; annealing, 55uCf o r1m i n( L I F ,1 8s )
or 65uC for 30 s (LIFR); extension, 72uC for 1 min; with a final
extension at 72uC for 10 min. Primers used were LIF (115 base pairs)
[24] fwd 59-TGA ACC AGA TCA GGA GCC T-39,r e v5 9-CCA
CAT AGC TTG TCC AGG TTG TT-39;L I F R( 3 5 6b a s ep a i r s )
[24] fwd 59-GTG GCA GTG GCT GTC ATT GTT GGA GTG
GT-39,r e v5 9- T C AT C TG C GG C TG G GT T TG G TA T TT C T
TC-39; 18 s (187 base pairs) fwd 59- GATCCATTG GAG GGCAA
GTC T-39,r e v5 9-CCA AGA TCC AAC TAC GAG CTT TTT-39.
The PCR products were run on a 1% agarose gel with 1000 bp DNA
ladder (Invitrogen) to semi-quantify LIF and LIFR expression.
LIF activation of STAT3 in HESC
Treatments. Confluent decidualized (D) or non-decidualized
(ND) HESC (25 cm
2 flask; cultured from individual endometrial
biopsies, n=3 women/group; ND incubated overnight in low-
serum media) were treated with LIF (5, 50, 100 and 200 ng/ml;
R&D systems) in serum-free media for 15 min. HESC were also
treated with a LIF antagonist (LA; a kind gift from Drs Nick
Nicola and Jianguo Zhang, Walter and Eliza Hall Institute) [25]
for 30 min prior to the addition of LIF (100 ng/ml).
pSTAT3/STAT3 Western blot. After LIF treatment the
medium was aspirated and cells were washed twice with ice cold
sterile PBS before being lysed as described above. Total cellular
protein (25 mg) was resolved on an 4–11% SDS/PAGE gel, then
transferred to Hybond-P PVDF membranes (GE healthcare,
Amersham, UK) before the membranes were probed for pSTAT3
and STAT3 (both Cell Signaling Technology) and densitometry
performed as previously described [26].
Effect of exogenous LIF on decidualization
HESC were induced to decidualize as described above. The
effect of LIF on decidualization (PRL secretion) was examined by
including exogenous human recombinant LIF (5, 50, 100 and
200 ng/ml; R&D systems) to the decidualization treatment (n=5/
group). Further, the effect of LIF inhibition on decidualization was
investigated by the addition of LA (10 mg/ml) from D8 of
treatment (50 ng/ml) in decidualizing HESC (n=3).
Cytokine secretion by 1
st trimester decidua parietalis and
decidualizing HESC
The secretion of specific cytokines by decidua parietalis biopsies
(decidua containing no extravillous trophoblast) or by decidualizing
HESC with LIF treatment (0.5 and 50 ng/ml) was investigated
using the Multiplex 12-plex Human Cytokine Assay Kit (Millipore,
MA, USA) following the manufacturer’s instructions. The kit
included FGF2, G-CSF,TNF-a, GM-CSF,IL-1b, IL-1ra, IL-6, IL-
8, IL-10, IL-15, MCP-1 and VEGF. The detection range of the
cytokines was from 3.2 pg/ml to 10,000 pg/ml. Data analysis of
samples and standards was performed by Bio-Plex manager
software version 4.0.1. For statistical analysis the multiplex data
was normalized to protein concentration and also prolactin
secretion to account for the differences in the degree of
decidualization found between cultures isolated from different
women and because LIF itself promoted decidualization thus
enhanced decidualization itself may have promoted cytokine
secretion, not LIF.
Decidual biopsy conditioned media. Decidual tissue
(n=3) was cut into thin squares (,2m m
3), and placed on top
of siliconised lens tissue paper [27] floating on 1 ml of serum-free
DMEM/F12 and cultured for 72 h at 37uC with 5% carbon
dioxide. Explant culture on siliconised lens paper facilitates both
the absorption of required nutrients from the medium and gas
exchange [27]. After culture, the conditioned media was collected
and concentrated 10-fold as described above. Representative
decidual explants were examined by histology for evidence of
necrosis and human leukocyte antigen (HLA) G
+ extravillous
trophoblast (data not shown).
HESC cell conditioned media. The conditioned media for
HESC was collected from HESC induced to decidualize as
described above in the presence of LIF (0.5 or 50 ng/ml) for 48 h
(n=5).
Inhibition of LIF action during early decidualization in
mice
Animals. Female (virgin 8–12 weeks old) and male C57BL/
6J mice (Monash Animal Services, Clayton, Australia) were
housed under conventional conditions, with food and water
available ad libitum and held in a 12 hr light and dark cycle.
Immunohistochemistry for LIF and LIFR. Inter- and
intra-implantation sites were collected from mated female mice
treated with 1000 mg PEG on Day (D) 5 of gestation (D0=day of
plug detection) and either fixed (,24 h) for histology in 10%
neutral buffered formalin or snap frozen.
Paraffin embedded, formalin fixed mouse implantation sites
(n=3 per group) were dewaxed and rehydrated in ethanol. LIF
and LIFR were immunolocalised as described above except that
the non-immune block used was: LIF: 10% normal goat plus 2%
normal mouse serum and LIFR: 10% normal horse and 2%
mouse serum; and two LIF antibodies were used to confirm the
specificity of LIF staining (rabbit anti-human LIF antibody as
above and in [20] and goat anti-human LIF antibody, R&D
systems; 10 mg/ml).
LIF ELISA. Frozen intra- and inter-implantation sites (n=3/
group) were homogenized and cells lysed in UIP lysis buffer as
described above. Total cellular protein (20 mg) was added to each
well of the Human LIF ELISA (ELH-LIF-001; RayBiotech) and
LIF detected according to the manufacturer’s instructions.
Western blotting for LIFRa. Frozen intra- and inter-
implantation sites (n=3/group) were homogenized and cells
lysed in UIP lysis buffer as described above. Total cellular protein
(20 mg) was resolved on an 4–11% SDS/PAGE gel, then
transferred to Hybond-P PVDF membranes (GE healthcare,
Amersham, UK) before the membranes were blocked in 3%
bovine serum albumin (BSA) and probed for LIFR (1:1000; R&D
Systems) and b-actin (1:2000, Cell Signalling Technology, HRP-
conjugated) overnight at 4uC or 1 h at RT. After washes in TBS
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secondary antibody (rabbit anti-goat, 1:4000, DAKO; b-actin,
sheep anti-mouse, Amersham) for 1 h at RT before antibody
binding was detected using Pierce ECL Western Blotting Substrate
(Thermo Scientific).
PEGLA treatment to block decidual LIF action. Polye-
thylene glycol (PEG) conjugated LIF-antagonist (PEGLA) [19] and
PEGylation reagent control were a kind gift from Drs Nick Nicola and
Jianguo Zhang (Walter and Eliza Hall Institute, Parkville, Victoria,
Australia). The LIF antagonist (LA) binds to the LIF receptor but does
not bind to the LIF receptor complex signalling component, gp130,
preventing the initiation of downstream signalling. LA was covalently
bound to PEG (PEGLA) to increase the period of sera retention [19].
PEGLA acts on the uterus to block implantation when delivered by
intra-peritoneal (IP) injection during the peri-implantation period
[19].
To inhibit LIF action in the endometrial stroma during early
decidualization, mated female mice received a single IP injection
of 900 or 1200 mg (150 or 200 mM; optimised from initial studies;
n=2–3/group) PEGLA or PEG control (equivalent molarity) at
10am on D4 of gestation immediately post-implantation which
begins at D3.5 [28] and mice were killed on D6 of pregnancy
when the implantation sites are clearly visible. Uterine horns were
removed and the number of implantation sites and corpora lutea
counted. Implantation sites were dissected out and fixed in 10%
neutral buffered formalin (,18 hrs).
Desmin immunohistochemistry. Paraffin-embedded, formalin-
fixed implantation sites were dewaxed in histosol and rehydrated
through ethanol to water. Endogenous hydrogen peroxidase
activity was quenched using 3% H2O2 in methanol for 10 min in
the dark at RT before being washed with high salt TBS (300 mM
NaCl, 5 mM TrisCl in distilled water pH 7.6). Sections were
blocked in non-immune serum (15% normal goat serum
0.1%Tween-20 high salt TBS) for 30 min at RT before
primary antibody was applied (Desmin, 2.9 mg/ml, M0760,
DAKO; negative: mouse IgG 2.9 mg/ml DAKO) in block (10%
normal goat serum in 0.1% Tween-20 high salt TBS) and
incubated for 30 min at RT. After stringent washing (265 min)
with 0.6% Tween-20 in high salt TBS, the Envision
+ system
labelled Polymer-HRP anti-mouse (K4001, DAKO) was applied
to sections for 30 m at RT. Sections were washed twice with
0.6% Tween-20 in high salt TBS and then twice with high salt
TBS before the substrate 393-diaminobenzidine (K3466, DAKO)
was applied. Quality controls were included in each run.
Immunostaining was analyzed semiquantitively by two
independent and blinded observers as previously described [26].
The intensity of desmin staining in the decidua was assessed and
allocated a score between 0 (no staining) and 3 (strong staining)
relative to positive and negative controls. The area of desmin
staining was quantified using Motic Images Plus 2.0 software
(Motic China Group Co Ltd).
Statistical analysis
GraphPad Prism 5.0 Windows (GraphPad Software, San Diego,
CA, USA) was used for all statistical analyses. Statistical advice was
obtained from Dr. Aidan Sudbury (statistician) at Monash
University. PRL secretion data was normalized to total cellular
protein and analyzed by the non-parametric Kruskal Wallis test.
Non-parametric t-test (Mann Whitney) was used to compare the
secretion of cytokines by decidualizing HESC. The weight, size of
decidual area and desmin intensity staining in mouse implantation
sites were compared by student’s t-test. All results are given as
mean 6 standard error of the mean (SEM). A P value of ,0.05
was considered significant.
Results
LIF and LIFR immunolocalized to decidual cells in the
mid-late secretory phase endometrium and 1
st trimester
decidua
Endometrial epithelial cells were a major source of LIF
immunoreactivity (Figure 1A). LIF immunoreactivity was also
found in the endometrial stroma during the mid-late secretory
phase, particularly in decidualized stromal cells located near spiral
arterioles and endothelial cells (Figure 1A). In first trimester
decidua, LIF immunoreactivity was strong in decidual cells and
present in endothelial cells and glandular epithelium (Figure 1B).
The LIFR localised to the glandular epithelium and in
decidualized stromal cells in the mid-late secretory phase
endometrium and in first trimester decidua (Figure 1C & D).
LIF and LIFR expression following decidualization
stimulus
LIF mRNA expression in HESC was down-regulated following
treatment with E+MPA compared to E or media control at D14 of
decidualization treatment (Figure 2). LIFR mRNA was expressed
following treatment with E alone and was up-regulated following
treatment with E+MPA (Figure 2) compared to control and E
groups at D14 of decidualization treatment.
LIF activated STAT3 in non-decidualized and decidualized
HESC
The effect of LIF on STAT3 phosphorylation (pSTAT3) in non-
decidualized (ND) and decidualized (D) HESC was examined by
Western blot (Figure 3A & B). pSTAT3 was not detectable in ND
Figure 1. LIF and LIFR immunolocalization in human endome-
trial biopsies. A. LIF immunolocalized to glandular epithelium (*),
endothelial cells (a) and decidualized stromal cells (arrows) during the
mid-secretory phase. B. LIF immunolocalized to decidual cells (arrows),
endothelial cells (a) and glandular epithelium (*) in 1
st trimester
decidua. C. LIFR immunolocalized to glandular epithelium (*) and
decidualized stromal cells (arrows) during the mid-secretory phase. D.
LIFR immunolocalized to decidual cells (arrows) in 1
st trimester decidua.
Representative photomicrographs from n=3. Scale, 100 mm; Insert,
negative (IgG) control; a, spiral arterioles.
doi:10.1371/journal.pone.0025288.g001
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Addition of LIF ($50 ng/ml) stimulated pSTAT3 abundance in
both ND and D HESC in a concentration-dependent manner
(Figure 3A & B) compared to respective control. Co-incubation of
LIF (100 ng/ml) plus LA (10 mg/ml) diminished STAT3 activa-
tion in ND and D HESC compared to LIF (100 ng/ml) alone
respectively (Figure 3A & B). STAT3 protein abundance was not
affected by LIF or/and LA treatment (Figure 3A & B) in both ND
and D HESC.
LIF enhanced HESC decidualization
HESC treated with media or E alone did not secrete detectable
levels of PRL on D14 (Figure 4A). HESC treated with E+MPA
secreted PRL on D14 (4.960.6 ng PRL/mg protein; Figure 4A).
PRL secretion by E+MPA-treated HESC (decidualizing) was
significantly enhanced following treatment with $50 ng/ml
exogenous LIF (50 ng/ml, 30.4617; 100 ng/ml 30.8617.7;
200 ng/ml, 30.9612.6 ng PRL/mg protein; Figure 4A; Kruskal-
Wallis statistic 27.73, df 7, p,0.05).
The specificity of LIF action was confirmed by co-treatment of
decidualizing HESC with LIF (50 ng/ml) +/2 LA (10 mg/ml;
Figure 4B). Co-incubation of decidualizing HESC with LIF plus
LA reduced PRL secretion to levels found in E+MPA alone on
D14 (E+MPA, 3.961.2; E+MPA+LIF, 41.0628.6; E+MPA+LI-
F+LA, 2.660.1 pg PRL/mg protein; Figure 4B; Kruskal-Wallis
statistic 9.462, df 4, p,0.05). Treatment of decidualizing HESC
with LA alone (no LIF treatment) to block endogenous LIF had no
effect on decidualization (E+MPA, 4.460.8; E+MPA+LA,
3.660.3 pg PRL/mg protein; Figure 4B).
LIF (50 ng/ml) modified cytokine secretion by
decidualizing HESC
First trimester decidual biopsies secreted detectable levels of all
cytokines examined except FGF2 (Figure 5A). The decidual
biopsies secreted high levels of G-CSF, GM-CSF, IL6, IL8 and
MCP1 (Figure 5A). Decidualized HESC secreted detectable levels
of only IL6, IL8, IL15 and MCP1 (Figure 5B). Addition of 50 ng/
ml LIF to the decidualizing HESC increased the secretion of IL6
and IL15 compared to 0.5 ng/ml LIF (IL6, 0.5 0.260.1, 50
2.361.0 pg/mg PRL/mg protein; Mann-Whitney U 2.0, p,0.05;
IL15, 0.5 0.360.1, 50 23.9620.9 pg/mg PRL/mg protein; Mann-
Whitney U 0.0, p,0.05). The trend was similar for IL8 and
MCP1 but did not reach statistical significance (Figure 5C–F).
LIF and LIFR immunolocalized to mouse implantation site
Mouse inter- and intra-implantation sites from day 5 of
gestation (post-implantation) showed LIF and LIFR immunolo-
calization predominantly in decidual cells and the luminal
epithelium (Figure 6A–F). LIF localized to the decidua
(Figure 6B&C) and also to the the luminal epithelium
(Figure 6C&D). LIFR localized to the decidua (Figure 6E–H).
LIFR was upregulated in implantation sites in mice
LIF protein was quantitated from inter-implantation
(11.367.3 pg/mg) and intra-implantation (12.866.8 pg/mg) sites
by ELISA. No significant difference was observed between inter-
implantation and intra-implantation sites (Figure 7A) however the
variance in LIF protein levels was quite high between mice (inter-
implantation 3.0 to 18.1 pg/mg vs intra-implantation 6.7 to
20.1 pg/mg).
LIFR protein was up-regulated in intra-implantation sites
compared to inter-implantation sites (Figure 7B).
PEGLA impaired decidualization in mice
PEGLA administered by IP injection on D2 and D3 acts as a
contraceptive by inhibiting attachment of the blastocyst to the
uterine luminal epithelium [19]. Using PEGLA, we aimed to
investigate the role of LIF during early decidualization in vivo in
mice. A single dose of 900 mg (n=2 PEGLA, n=3 PEG) or
1200 mg (n=2/group) PEGLA or PEG control at 10am D4
resulted in smaller decidual area (assessed by area of desmin
staining: PEGLA 1.060.3 mm
2, PEG 2.260.4 mm
2,n = 4
PEGLA, 5 PEG; t7 2.387, p,0.05; Figure 8A–C) and less intense
desmin immunoreactivity of decidual cells (PEGLA 1.060.16,
PEG 2.360.1, n=5/group; t8 6.500, p,0.05; Figure 8D–F) in
PEGLA treated implantation sites compared to PEG control
implantation sites. We have pooled the data from our two PEGLA
treatments (900 mg and 1200 mg/injection) as no difference in
decidual morphology was observed between the two doses.
Discussion
Decidualization is a tightly regulated process, characterised by
the sequential expression of regulatory genes [1]. A number of
factors enhance progesterone-induced HESC decidualization and
here we demonstrated that exogenous LIF enhanced MPA-induced
decidualization of HESC in vitro. Further, LIF regulated IL6 and
Figure 2. LIF and LIFR mRNA expression in non-decidualized
(media control [C] and estradiol [E] treated) and decidualized
(E plus medroxy-progesterone acetate [MPA] treated) HESC
determined by semi-quantative reverse-transcription PCR. 18 s
ribosomal RNA was used as loading control. LIF expression was
downregulated by E+MPA, whilst LIFR expression was stimulated by
both E and particularly E+MPA. Representative gel of n=5.
doi:10.1371/journal.pone.0025288.g002
Figure 3. Leukemia inhibitory factor (LIF) activated STAT3 in
HESC. Cells were treated with LIF for 15 min and with a LIF antagonist
(LA) for 30 min prior to the addition of LIF. A. Representative
immunoblot for pSTAT3 and total STAT3 in cell lysates from non-
decidualized HESC (n=3). B. Representative immunoblot for pSTAT3
and total STAT3 in cell lysates from decidualized HESC (n=3).
doi:10.1371/journal.pone.0025288.g003
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mechanisms of LIF action during HESC decidualization. Similarly
in mice, we showed that administration of a LIF inhibitor post-
implantation retarded decidualization. Both LIF and LIFR
immunolocalized to decidual cells post-implantation in mice. This
study showed that LIF is functionally important for decidualization
in both human and murine endometrial stromal cells.
Previous studies have suggested that LIF protein production in
the human uterus is mainly localized to the glandular epithelium
[29,30,31,32], however LIF-immunoreactive cells are localized to
first trimester decidua [31,32] as was found here. LIFR mainly
localized to the epithelium, but was also present in decidualizing
stromal cells [24] and 1
st trimester decidual cells.
Our in vitro data (mRNA expression of LIF in cultured HESC)
suggests it is likely that the immunoreactive LIF in decidual cells is
endogenously produced, however we were unable to detect
secreted LIF protein by HESC in vitro (data not shown). We
did not measure cellular LIF protein. Previous studies have shown
that LIF is secreted from decidual biopsies, but not from isolated
cells, either decidual or leukocyte [33] and estrogen induces the
secretion of LIF by decidual cells isolated from first trimester
decidua [32], however, these decidual cells are a lot further
decidualized than the decidualizing HESC assayed here. Here,
treatment of decidualizing HESC with LA alone did not affect
decidualization, suggesting that any endogenous LIF produced
(mRNA or protein) in our system was not active. Certainly, our
decidualization stimulus (E+MPA) actually suppressed LIF mRNA
expression in HESC compared to non-decidualized control.
Interestingly, hCG, via prokineticin induces LIF mRNA in
decidua [34], suggesting that it may be hCG which up-regulates
decidual LIF production during pregnancy. Taken together, these
data suggest that LIF is produced by decidual cells in vivo but that
it is regulated by factors not present in our in vitro system.
Here for the first time we showed hormonal (E+MPA)
regulation of LIFR mRNA in HESC. Hormonal regulation of
LIFR occurs in sheep [35] and is likely also occuring in mice and
hamsters where LIFR mRNA expression is up-regulated during
decidualization whereas LIF is transiently expressed [5,36,37].
Figure 4. Exogenous LIF enhanced estradiol (E) + medroxy-progesterone acetate (MPA)-induced in vitro decidualization (measured
by PRL secretion) in HESC. A. LIF treatment significantly (*; p,0.05) promoted E+MPA-induced decidualization in HESC compared to E+MPA-
treated control on D14 (n=5). B. Co-incubation of E+MPA plus LIF and LIF antagonist (LA) significantly (*; p,0.05) inhibited HESC decidualization
compared to HESC treated with E+MPA plus LIF (n=3). Treatments: E 10
28 M; MPA 10
27 M.
doi:10.1371/journal.pone.0025288.g004
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PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e25288Figure 5. LIF (50 ng/ml) enhanced IL6 and IL15 secretion by in vitro decidualized HSEC. A. Cytokine secretion by first trimester decidual
biopsies (n=3). B. Cytokine secretion by HESC decidualized with estradiol (E) and medroxy-progesterone acetate (MPA) (n=5). C. LIF treatment
(50 ng/ml) significantly (*; compared to 0.5 ng/ml; p,0.05) induced IL6 secretion by decidualized HESC (n=5). D. LIF treatment (50 ng/ml) had no
significant effect (compared to 0.5 ng/ml; p=0.222) on IL8 secretion by decidualized HESC (n=5). E. LIF treatment (50 ng/ml) significantly
(*; compared to 0.5 ng/ml; p,0.05) induced IL15 secretion by decidualized HESC (n=5). F. LIF treatment (50 ng/ml) had no significant effect
(compared to 0.5 ng/ml; p=0.222) on MCP1 secretion by decidualized HESC (n=5).
doi:10.1371/journal.pone.0025288.g005
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PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e25288Interestingly, our data showed that the LIFR was up-regulated by
the decidual stimulus: suggesting the decidualization stimulus
‘primed’ HESC to be responsive to LIF. Such ‘priming’ of
decidualizing HESC to respond to local factors has also been
demonstrated for total STAT3. STAT3 is present in decidualizing
cells of the mid-late secretory phase [21] and 1
st trimester decidua
[38] and our in vitro studies show that the decidual stimulus
induces production of STAT3 protein by HESC [21], enhancing
the ability of HESC to respond to cytokines such as IL11 and
possibly LIF that signal via STAT3 activation. Taken together,
this data suggests that the decidualization stimulus amplifies the
response of HESC to LIF.
In a previous study, exogenous LIF had no effect on cAMP-
induced HESC decidualization [8]. Medoxy-progesterone acetate
(MPA; a stable synthetic progestin) was chosen for the present study
as progesterone is the main physiological inducer of decidualization
in vivo and other cytokines have been shown to progress
progesterone-induced decidualization including IL11 and activin
A whilst havingnoeffectoncAMP-induceddecidualization [12,21].
cAMP and progesterone use different pathways during decidualiza-
tion [10] and cAMP is thought to prime HESC to the action of
progesterone [10], however both pathways are nevertheless
required for the progression of normal decidualization [9].
We also examined the downstream actions by which LIF may
regulate decidualization. First trimester decidual biopsies secreted
high levels of G-CSF, GM-CSF, IL6, IL8 and MCP1 and
correspondingly, decidualized HESC secreted high levels of IL6,
IL8, IL15 and MCP1. It should be noted that decidual biopsies
contain a large number of haematopoietic and other cells, thus this
secretome represents more than just decidual secretions, however
our data suggests that decidual cells may secrete IL6, IL8 and
MCP1. Here, we report for the first time that LIF enhanced IL6
and IL15 secretion by decidualized HESC. IL15 is expressed by
first trimester decidua [39,40] and is up-regulated during P-
induced HESC decidualization in vitro [40]. Implantation sites in
IL15 null female mice lack decidual integrity as well as having an
absence of uterine natural killer cells [41]. It remains to be
Figure 6. LIF and LIFR immunolocalized to decidualizing stromal cells on Day 5 of gestation in mice. A–D. LIF immunolocalized strongly
to the decidua (d) and also to the luminal epithelium (le). E–H. LIFR immunolocalized strongly to the decidua. Bottom row, negative controls to
sections above. The same negative is shown for both antibodies as the primary antibodies shown were both raised in goat. n=3; m. myometrium; s,
stroma.
doi:10.1371/journal.pone.0025288.g006
Figure 7. LIF and LIFR protein in murine inter- and intra-
implantation sites. A. LIF protein in cellular extracts quantified by
ELISA (inter- and intra-implantation sites from n=3 independent
animals). B. LIFR protein in cellular extracts quantified by Western blot
(inter- and intra-implantation sites from n=3 independent animals).
doi:10.1371/journal.pone.0025288.g007
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and whether this also occurs in mice. LIF also up-regulated IL6
secretion by decidualizing HESC. IL6 has only been identified in
the decidua in one previous study which used RNA arrays to
investigate the effect of trophoblast conditioned media on stromal
decidualization [42]. Future studies are required to determine
nature of the interaction between LIF and IL6 and IL15.
In mice, decidualization progresses from the anti-mesometrial to
the mesometrial region as stromal cells proliferate and enlarge
[43]. We have shown LIF and LIFR protein localization to murine
decidual cells and previous studies have shown the LIF signalling
molecules STAT3 [44] and gp130 [37] are present in the mouse
decidua. Intriguingly, LIFR mRNA (shown by in situ hybridiza-
tion) was expressed by decidual cells just beneath the luminal
epithelium on D5 of gestation [37] but our data suggests that the
LIFR protein localized to decidualized cells throughout the
implantation site. We confirmed the strong expression of LIFR
in the decidua by Western blotting, where implantation sites,
which by immunohistochemistry contained mainly decidual cells,
had increased LIFR compared to inter-implantation sites, which
contained no decidual cells.
Administration of our long-acting LIF antagonist (PEGLA) to
mice during the initial stages of decidualization, which, unlike in
women occurs only post-implantation in mice, resulted in reduced
decidual area and reduced immuno-intensity of desmin, a decidual
marker compared to control. Altogether, our data suggests that the
LIF antagonist acted on decidual cells to suppress decidualization.
Previous studies have indicated that LIF may enhance murine
decidualization: LIF
2/2 females cannot undergo artificially in-
duced decidualization [14]. Intra luminal injection of a short-acting
LIF inhibitor (LIF05, prior to implantation on D3) inhibited
blastocyst attachment [15] and therefore decidualization, shown by
a reduction in desmin filaments compared to control treated mice.
This study also suggests that LIF acts via the luminal epithelium,
whilst further demonstrating that LIF canalso independently actvia
the decidual cells themselves to stimulate decidualization. Support-
ing this, intraluminal administration of LIF partially rescues the
artifical decidual response in ovariectomized Foxa2 null mice which
have an attenuated decidualization response [16]. Paradoxically,
inhibition of LIF in cultured murine stromal cells undergoing in vitro
decidualization enhances decidualization while exogenous LIF
inhibits decidualization [17], suggesting that LIF may have an
inhibitory effect on in vitro decidualization of murine stromal cells,
opposite to in vivo studies. This study is the first to demonstrate that
LIF is critical for decidualization following natural (LIF dependent)
blastocyst attachment.
We have previously shown that PEGLA administration on D2
and D3 completely prevents implantation [19], thus, no decidual
reaction is initiated. Using a short-acting LIF inhibitor Mohamet
et al [15] showed that epithelial LIF signalling is critical for
attachment only between mid-morning and mid-afternoon on D3.
It is unlikely that PEGLA merely delayed implantation in our
study as initial blastocyst attachment begins on D3.5 [28] and we
did not begin injections until D4. Therefore PEGLA likely
inhibited LIFR signalling post-implantation in the implantation
site, leading to impaired decidual expansion.
Figure 8. In vivo LIF inhibition impaired decidualization in mice. A–B. PEG (control) implantation sites (A; n=5) had larger decidual areas
(identified by desmin staining, brown) than PEGLA-treated implantation sites (B; n=4). C. Graphical representation of the decidual area (identified by
area of desmin staining) in implantation sites on D6. D–E. PEG control treated implantation sites (D; n=5) showed stronger staining intensity of
desmin (brown, arrows) than PEGLA-treated implantation sites (E; n=4). F. Graphical representation of desmin staining intensity in decidual cells on
D6. *. Significant difference between treatments, p,0.05; Scale 2.0 mm (A&B); 500 mm (D&E).
doi:10.1371/journal.pone.0025288.g008
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PLoS ONE | www.plosone.org 9 September 2011 | Volume 6 | Issue 9 | e25288All together, this study showed that LIF enhanced decidualiza-
tion in both human and mouse models. We have identified a new
role for LIF in implantation and suggest that LIF could be a useful
target to either facilitate or block decidualization during the
earliest stages of pregnancy.
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